UROGEN PHARMA LTD. Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
(e)
On
The foregoing summary of the changes to the 2017 Plan made pursuant to the adoption of the 2017 Amended Plan at the Annual Meeting is qualified in its entirety by reference to the full text of the 2017 Amended Plan, a copy of which is filed as Exhibit 10.1 to this report and is incorporated by reference herein.
Item 5.07 Submission of Matters to a Vote of Security Holders.
At the Annual Meeting, the Company's shareholders voted on the proposals listed below, each of which was described in the Company's proxy statement for the Annual Meeting. The voting results are set forth below.
Proposal No. 1 - Election of Directors
The shareholders elected the following eight individuals to serve as directors until the Company's next annual meeting of shareholders and until their successors are elected. There were no nominees other than those listed below. The voting results are as follows:
Name Votes For Votes Withheld Broker Non-Votes Arie Belldegrun 9,864,608 502,684 4,029,358 Elizabeth Barrett 10,219,003 148,289 4,029,358 Cynthia M. Butitta 9,737,090 630,202 4,029,358 Fred E. Cohen 10,018,592 348,700 4,029,358 Kathryn E. Falberg 8,535,766 1,831,526 4,029,358 Stuart Holden 10,210,341 156,951 4,029,358 Ran Nussbaum 9,901,326 465,966 4,029,358 Shawn C. Tomasello 8,534,715 1,832,577 4,029,358
Proposal No. 2 - 2017 Amended Plan.
The shareholders voted to approve the 2017 Amended Plan. The voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 8,621,564 1,732,743 12,985 4,029,358
Proposal No. 3 - Advisory vote on the compensation of the Company's named executive officers.
On an advisory basis, the shareholders voted to approve the compensation paid to the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting. The voting results are as follows:
Votes For Votes Against Abstentions Broker Non-Votes 8,078,470 2,281,140 7,682 4,029,358
Proposal No. 4 - Engagement of
The shareholders approved the engagement of
--------------------------------------------------------------------------------
Votes For Votes Against Abstentions Broker Non-Votes 14,388,460 6,076 2,114 0
Brokers were entitled to cast votes on this proposal without voting instructions from the beneficial owners of the shares. As a result, there were no broker non-votes with respect to this proposal
Item 9.01 Financial Statements and Exhibits.
(d) Exhibit Number Description 10.1UroGen Pharma Ltd. 2017 Equity Incentive Plan, as amended. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
--------------------------------------------------------------------------------
© Edgar Online, source
